ArticleCureus2025
Cannabinoid Hyperemesis Syndrome Presenting as Postoperative Nausea and Vomiting in a Chronic Cannabis User: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition seen in chronic cannabis users, marked by recurrent nausea, vomiting, and abdominal discomfort. Although more widely recognized in emergency medicine, CHS remains underdiagnosed in the perioperative setting, where its symptoms may be misattributed to common postoperative phenomena such as anesthetic effects, opioid-induced nausea, or surgical complications. This diagnostic gap can delay appropriate management and lead to unnecessary interventions. We report the case of a 40-year-old woman with a two-year history of daily cannabis use who underwent a laparoscopic hysterectomy, mid-urethral sling placement, and pelvic organ prolapse repair. In the immediate postoperative period, she experienced persistent nausea and vomiting despite the administration of multiple antiemetics, including ondansetron and metoclopramide, and opioids for pain control. By postoperative day 2, vomiting occurred in discrete, refractory episodes despite continued pharmacologic management, prompting concern for an atypical cause. The patient was placed on nil per os (NPO) status, but symptoms escalated on postoperative day 3, culminating in a prolonged episode of emesis accompanied by hematemesis and hallucinations. At this stage, CHS was strongly suspected given her chronic cannabis use, clinical trajectory, and lack of response to standard therapies. Supportive care was intensified with intravenous hydration and electrolyte replacement for significant hypokalemia and hypophosphatemia. The patient's condition stabilized over the next 24 hours, with gradual resolution of symptoms and resumption of oral intake by postoperative day 4. She was discharged in stable condition with a tailored regimen of antiemetics, analgesics, and counseling on cannabis cessation. She abstained from cannabis throughout hospitalization. This case highlights a critical but underrecognized cause of refractory postoperative nausea and vomiting (PONV). In patients with a history of chronic cannabis use, perioperative teams should maintain a high index of suspicion for CHS when standard antiemetic regimens fail. Early identification not only prevents unnecessary diagnostic testing and extended hospitalization but also enables more effective patient education and targeted counseling. Broader awareness of CHS among surgical and anesthesia teams can improve outcomes through timely diagnosis, supportive care, appropriate discharge planning, and public health efforts to raise awareness of cannabis-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.